Oral Thrombin Inhibitors for State of the Art Atrial Fibrillation: Is There a Winner? - C. Michael Gibson, MD

↳ This is a section part of Moment: CRT 2015 Coronary - The Oral Factor Xa Inhibitor Controversy

Add this Moment to your Passport

Learn from this moment and keep it forever.
Add To Passport
$9.99
This moment is included in Simple Premium - Get started for free.
FREE with Simple Premium
Start your 30-day free trial
Simple Premium offers unlimited access to all premium moments. $30.00 per month. Cancel anytime.

Preview

Summary

Oral Thrombin Inhibitors for State of the Art Atrial Fibrillation: Is There a Winner? presented by C. Michael Gibson, MD at CRT 2015

Add this Moment to your Passport

Learn from this moment and keep it forever.
Add To Passport
$9.99
This moment is included in Simple Premium - Get started for free.
FREE with Simple Premium
Start your 30-day free trial
Simple Premium offers unlimited access to all premium moments. $30.00 per month. Cancel anytime.

Target Audience

  • Interventional Cardiologists
  • Interventional Fellows

Session Name: The Oral Factor Xa Inhibitor Controversy

Track: Coronary

Learning Objectives

  • Update in advances in ACS & AMI Management

Other Components in this Moment

Overview
Oral Thrombin Inhibitors for State of the Art Atrial Fibrillation: Is There a Winner? - C. Michael Gibson, MD
Dabigatran: Are There Any Concerns? - Neal S. Kleiman, MD
Can we Combine Antiplatelet Therapy with Oral Factor Xa Inhibitors? - D. Angiolillo, MD, PhD
Rivaroxaban in Patients with ACS: Does the Data Support its Routine Use? - C. Michael Gibson, MD
When Should Aspirin Be Dropped From Triple Therapy? - Samir Pancholy, MD
Inhibition and Modulation Factor IX Activity with a Novel Aptamer System during PCI - Rationale for the REGULATE Trial - A. Michael Lincoff, MD
Loading Simple Education